Ask the Experts’ Office

Define the facility, operations and products in scope. The Office’s self-check helps identify gaps and prioritise improvements; connect each finding to an existing record or procedure and a follow-up action. The assessment supports preparation and is not a compliance certificate or a substitute for an inspection.

No. Good manufacturing practice covers the design, monitoring and control of processes and facilities, alongside personnel, materials and quality systems. Product testing is one part of this system; it does not replace the controls needed during manufacture.

Start with the country, product type and application stage. Use the Registration Navigator to locate the relevant pathway and requirements, then consult the national authority’s document and its date. Keep a product-specific list of documents and open questions; do not apply one country’s requirements to every market.

A biopharmaceutics classification system based biowaiver may be appropriate for some Class I and Class III products when the applicable guideline’s conditions are met. Classification alone does not establish eligibility: consider the product, drug substance, dissolution, excipients and the receiving authority’s requirements.

A biosimilar is a biological medicine highly similar to an already approved reference biological medicine. Comparability concerns quality, biological activity, safety, efficacy and immunogenicity; a similar name or substance alone is not sufficient evidence. The Office’s studio helps organise the development evidence and comparator choices.

Examine what changed, who changed it, when it changed and whether the change affects interpretation of the result. Copies used as records should preserve the original content, meaning and necessary metadata. FDA guidance links the review approach and frequency to data criticality, processes and risk.

Bring together source, stock, shipping-route, lead-time and alternative-supply data. Use the Supply Resilience Studio to compare scenarios and record the assumptions behind each one. Review the effect on production continuity alongside the purchase price.

WHO publishes good storage and distribution practices for medical products in Annex 7 of Technical Report Series 1025. Use it alongside national requirements and the product’s storage and handling conditions. Product-specific data and circumstances remain necessary when assessing an actual event.

Identify the product, formulation, packaging, target markets and available stability data. The Stability Studio brings together temperature, humidity, climatic zones and excursion topics. Check the conditions and reference applicable to your product; a general description cannot establish shelf life.

The QC studio groups resources on out-of-specification and out-of-trend investigations, method validation and system suitability. Bring the original result, method and supporting records to identify the review route under your facility’s procedure. A general answer here cannot invalidate a result or authorise batch release.

Start with the device’s intended purpose, use and target market. The Medical Device Studio connects classification with registration pathways and relevant standards. Confirm your choice against the competent authority’s document; a short device description is not enough for a final classification.

The Falsified Products Studio brings together traceability resources, warning signs and response pathways. Use product, batch and source details to locate the relevant documents, then follow the competent authority’s procedure in your market. A photograph or a single feature cannot establish authenticity or falsification.

Describe the proposed change, components, use and target markets. The studio helps explore the regulatory basis, combination rationale and evidence package. A commercial label or description as value-added does not, by itself, determine the application pathway.

Collect active-ingredient and excipient origins, supporting documents, manufacturing and segregation information. The studio supports excipient screening and readiness review. Identify the standard and certification body required for your market; using the tool does not certify a product.

Supply Watch groups disruption and shortage signals, while the Resilience Studio helps examine their effect on your facility. Check the signal’s date, source and geographic scope before using it in a supply scenario.

Use the Renewal & Variation Tracker to organise registered products, markets, action types and dates. Base each file on the authority’s date and document, and identify an internal owner for follow-up. Do not treat an estimated date as an official deadline.

Prepare the proposal’s assumptions, alternatives, costs, risks and supporting data. The Boardroom groups comparison, analysis and decision-record tools. Outputs support discussion and do not guarantee investment returns; distinguish established information from points requiring verification.

Open the Morning Brief or Regulatory Index. Published entries carry a date and source, and may include document status or a comment or effective date. The time data reaches the page is different from the news date; check both when assessing freshness.

Change Radar focuses on developments from Arab medicines authorities. The Regulatory Index groups Arab and international updates with their links. Use both with publication dates and sources, and open the original document when an update affects your file or procedure.

The Regulatory Report is available through the Office’s current resources, with other series and dated editions in the knowledge archive. When citing a report, record its title, edition, date and link rather than only citing a changing landing page.

Start with the API & Excipient Data Bank for resources on materials, origins and supply routes. For research, use the stable dataset page and record its displayed edition and date. Listing a supplier in a directory is not equivalent to qualifying it for your product.

The platform brings together inspection tools, documented records, finding-writing resources and review outputs. Open the current inspection dashboard for operational use; its records and permissions remain in the existing system.

Start by describing the product, process, potential contamination routes and existing barriers. The Office groups strategy elements, tables and control-assessment tools. Use the outputs to review how barriers work together and what evidence supports their effectiveness, with the reference applicable to the process.

The current diploma page contains courses, films and assessments within the published programme. Open the programme page for registration conditions, dates and content access. Restricted materials continue to use existing accounts and permissions.

Start with the Research Hub to identify datasets and scientific evidence relevant to your question. Use stable dataset pages for citation, including the edition and collection date shown at the source. Read the original study or document before carrying its conclusion into your work.

Describe the problem, stage and output you need, then search the Technical Solutions Bank or resource directory. The directory connects Office topics with the original tool or reference. For a product- or facility-specific case, prepare the relevant details for a specialist discussion.

You can open the current Expert Forums to ask a question and exchange experience under their rules. Instant answers here use reference content and do not represent a human expert being online. Live expert Q&A is planned; its launch date has not been announced.

Pharmacovigilance monitors medicine and vaccine safety throughout the product lifecycle and supports reliable exchange of benefit–risk information. WHO provides resources for monitoring systems. Actual case reports follow the competent authority’s stated channel and procedure; this page does not collect case reports.